ES2078447T3 - Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales. - Google Patents

Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.

Info

Publication number
ES2078447T3
ES2078447T3 ES91305432T ES91305432T ES2078447T3 ES 2078447 T3 ES2078447 T3 ES 2078447T3 ES 91305432 T ES91305432 T ES 91305432T ES 91305432 T ES91305432 T ES 91305432T ES 2078447 T3 ES2078447 T3 ES 2078447T3
Authority
ES
Spain
Prior art keywords
crystals
improve
size
crystallization procedure
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91305432T
Other languages
English (en)
Inventor
Michael Midler Jr
Paul D Liu
Edward L Paul
Mauricio Futran
Edwin F Whittington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065873&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2078447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2078447T3 publication Critical patent/ES2078447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0009—Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0018—Evaporation of components of the mixture to be separated
    • B01D9/0027—Evaporation of components of the mixture to be separated by means of conveying fluid, e.g. spray-crystallisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/20—Jet mixers, i.e. mixers using high-speed fluid streams
    • B01F25/23—Mixing by intersecting jets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30—Micromixers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/8593—Systems
    • Y10T137/87571—Multiple inlet with single outlet
    • Y10T137/87652—With means to promote mixing or combining of plural fluids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

CORRIENTES EN CHORRO DE INCIDENCIA DE FLUIDOS SON UTILIZADOS EN UN PROCESO DE CRISTALIZACION CONTINUO PARA CONSEGUIR UNA MICROMEZCLA DE FLUIDOS DE ALTA INTENSIDAD COMO PARA FORMAR UNA COMPOSICION HOMOGENEA ANTES DEL COMIENZO DE LA NUCLEACION. ESTE PROCESO PERMITE CRISTALIZACION DIRECTA DE PARTICULAS DE GRAN AREA DE SUPERFICIE DE ALTA PUREZA Y ESTABILIDAD.
ES91305432T 1990-06-15 1991-06-14 Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales. Expired - Lifetime ES2078447T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53861190A 1990-06-15 1990-06-15
US70668291A 1991-06-03 1991-06-03

Publications (1)

Publication Number Publication Date
ES2078447T3 true ES2078447T3 (es) 1995-12-16

Family

ID=27065873

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91305432T Expired - Lifetime ES2078447T3 (es) 1990-06-15 1991-06-14 Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.

Country Status (7)

Country Link
US (1) US5314506A (es)
EP (1) EP0461930B1 (es)
JP (1) JP3282731B2 (es)
CA (1) CA2044706C (es)
DE (1) DE69112917T2 (es)
ES (1) ES2078447T3 (es)
IE (1) IE67187B1 (es)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE161742T1 (de) * 1992-10-06 1998-01-15 Merck & Co Inc Kristallisationsvorrichtung mit zwei strahlen
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
JP3755826B2 (ja) * 1993-12-09 2006-03-15 触媒化成工業株式会社 アルミナの製造方法と装置
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5891526A (en) * 1995-12-01 1999-04-06 International Business Machines Corporation Apparatus for mixing a multi-component encapsulant and injecting it through a heated nozzle onto a part to be encapsulated
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
GB9702886D0 (en) * 1996-09-28 1997-04-02 Agglomeration Technology Ltd Spray crystallised products and processes
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20020151729A1 (en) * 1997-02-26 2002-10-17 Cheng Wen J. Novel process for the preparation of form 1 ranitidine hydrochloride
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US6467947B1 (en) * 1997-08-19 2002-10-22 Commonwealth Scientific And Industrial Research Organisation Method and apparatus for mixing
GB2341120B (en) 1998-09-04 2002-04-17 Aea Technology Plc Controlling uniformity of crystalline precipitates
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
CN1182903C (zh) 1999-01-29 2005-01-05 布里斯托尔-迈尔斯斯奎布公司 声波冲击喷射结晶设备和工艺
US6234664B1 (en) 1999-02-26 2001-05-22 Microtrac, Inc. Mixing reservoir for an automated recirculating particle size analysis system
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6546359B1 (en) 2000-04-24 2003-04-08 Sun Microsystems, Inc. Method and apparatus for multiplexing hardware performance indicators
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
IL156310A0 (en) * 2000-12-22 2004-01-04 Baxter Int Method for preparing submicron particle suspensions
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20050009908A1 (en) * 2001-08-06 2005-01-13 Hedberg Pia Margaretha Cecilia Aqueous dispersion comprising stable nonoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
EP1423096B1 (en) * 2001-08-29 2006-08-16 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
DE60227691D1 (de) 2001-11-01 2008-08-28 Nektar Therapeutics Sprühtrocknungsverfahren
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
WO2003092852A1 (en) * 2002-04-29 2003-11-13 Bristol-Myers Squibb Company Crystallization system utilizing atomization
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2005525227A (ja) * 2002-05-10 2005-08-25 ブリストル−マイヤーズ　スクイブ　カンパニー 均質化を用いる結晶化システム
US20030227820A1 (en) * 2002-06-05 2003-12-11 Parrent Kenneth Gaylord Apparatus for mixing, combining or dissolving fluids or fluidized components in each other
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
ES2206065B1 (es) 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
US20040185110A1 (en) * 2002-11-08 2004-09-23 Ronald Harland Formulations of low solubility bioactive agents and processes for making the same
US20040098839A1 (en) * 2002-11-27 2004-05-27 Pfizer Inc. Crystallization method and apparatus using an impinging plate assembly
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
JP4808970B2 (ja) 2002-12-30 2011-11-02 ネクター セラピューティクス 噴霧乾燥システム
GB0300339D0 (en) * 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
TW200417371A (en) * 2003-02-21 2004-09-16 Upjohn Co A continuous process for the production of R-rofleponide
CA2517727C (en) * 2003-03-04 2012-09-04 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization device and process
US20080194868A1 (en) * 2003-03-04 2008-08-14 Kozyuk Oleg V Hydrodynamic cavitation crystallization device and process
US7041144B2 (en) * 2003-03-04 2006-05-09 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization process
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
JP4652229B2 (ja) * 2003-03-27 2011-03-16 三井化学株式会社 ビスフェノールａの製造方法
GB2401547B (en) 2003-05-08 2005-07-20 Nektar Therapeutics Uk Ltd Particulate materials
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
ITTO20030474A1 (it) * 2003-06-23 2004-12-24 Rotta Res Lab Spa Ora Rottapharm Spa Procedimento per la preparazione di dexloxiglumide
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
WO2005058835A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
BRPI0509506A8 (pt) * 2004-04-01 2017-01-24 Pharmacia & Upjohn Co Llc Forma cristalina de pirazóis, processo para a conversão da mesma, composição farmacêutica, uso, processo para tornar a forma cristalina e processo para a produção da referida forma
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7314516B2 (en) * 2004-12-29 2008-01-01 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization device and process
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
DE102005053862A1 (de) 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
US20090111997A1 (en) * 2005-11-23 2009-04-30 Aaron Cote Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals
EP1919453A2 (en) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Processes for reducing particle size of aripiprazole
US20100041906A1 (en) * 2006-01-26 2010-02-18 Fuji-Film Manufacturing Europe B.V. Method for the precipitation of organic compounds
KR20080110807A (ko) * 2006-03-14 2008-12-19 머크 앤드 캄파니 인코포레이티드 마이크로 분쇄 및 마이크로-시드상의 결정화에 의한 결정성유기 미세입자 조성물의 생성 방법과 장치 및 이의 용도
US20070218141A1 (en) * 2006-03-15 2007-09-20 Ashis Kumar Mehta Simvastatin compositions
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CA2650395A1 (en) * 2006-04-28 2007-11-08 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US20090306339A1 (en) * 2006-09-19 2009-12-10 Van Boxtel Huibert Albertus Preparation of Fine Particles
KR20090082209A (ko) * 2006-10-10 2009-07-29 얀센 파마슈티카 엔.브이. 신규 (ｓ)-(＋)-2-(2-클로로페닐)-2-하이드록시-에틸 카바메이트 결정
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US8187554B2 (en) * 2008-04-23 2012-05-29 Microfluidics International Corporation Apparatus and methods for nanoparticle generation and process intensification of transport and reaction systems
WO2009131930A1 (en) * 2008-04-23 2009-10-29 Merck & Co., Inc. Nanoparticle formation via rapid precipitation
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
AU2010261509A1 (en) * 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
MX338211B (es) 2009-10-22 2016-03-30 Api Genesis Llc Metodos para hacer y utilizar composiciones que comprenden flavonoides.
KR101823706B1 (ko) 2010-03-22 2018-01-30 인스틸로 게엠베하 마이크로입자 또는 나노입자의 제조 방법 및 제조 장치
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) * 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
KR101959934B1 (ko) 2010-09-28 2019-03-19 다우 글로벌 테크놀로지스 엘엘씨 직교류 장애물을 구비한 반응성 유동 정적 혼합기
US10350556B2 (en) 2011-01-07 2019-07-16 Microfluidics International Corporation Low holdup volume mixing chamber
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
US9079140B2 (en) 2011-04-13 2015-07-14 Microfluidics International Corporation Compact interaction chamber with multiple cross micro impinging jets
US9199209B2 (en) 2011-04-13 2015-12-01 Microfluidics International Corporation Interaction chamber with flow inlet optimization
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
US9732068B1 (en) 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
CN103551100B (zh) * 2013-10-31 2015-10-28 华南理工大学 一种连续快速反应结晶提高晶体稳定性的装置及方法
US9993436B2 (en) 2014-12-12 2018-06-12 New Jersey Institute Of Technology Porous hollow fiber anti-solvent crystallization-based continuous method of polymer coating on submicron and nanoparticles
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
JP6442715B2 (ja) * 2017-04-28 2018-12-26 エム・テクニック株式会社 微粒子の製造方法
CN107551599B (zh) * 2017-10-24 2019-10-22 东南大学 多段进料式反溶剂喷射结晶器及其喷射结晶方法
US11634368B2 (en) 2018-03-28 2023-04-25 Jrx Biotechnology, Inc. Agricultural compositions
US11191723B2 (en) 2018-06-22 2021-12-07 Delphi Scientific, Llc Apparatus, systems, and methods for continuous manufacturing of nanomaterials and high purity chemicals
US20210369667A1 (en) 2019-03-29 2021-12-02 Vizuri Health Sciences Consumer Healthcare, Inc. Compositions and methods for the prevention and treatment of radiation dermatitis, eczema, burns, wounds and certain cancers
CN114262316A (zh) * 2021-12-24 2022-04-01 嘉应学院 纳米橙皮素、其制备方法及所用双匀浆空化射流***
CN115253367A (zh) * 2022-08-31 2022-11-01 浙江新和成股份有限公司 一种布洛芬微晶的生产装置及结晶方法和产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751335A (en) * 1951-02-01 1956-06-19 Exxon Research Engineering Co Method and apparatus for mixing and contacting fluids
US3622496A (en) * 1969-12-04 1971-11-23 Exxon Research Engineering Co Low-pour dewaxing process utilizing dual solvents
DE3126854C2 (de) * 1981-07-08 1984-09-27 Nukem Gmbh, 6450 Hanau Verfahren und Vorrichtung zur Herstellung kugelförmiger Teilchen aus spontan reagierenden flüssigen Komponenten
DE3569201D1 (en) * 1984-03-30 1989-05-11 Kawasaki Steel Co Crystallization apparatus for metal stripping
US4567912A (en) * 1984-07-30 1986-02-04 Acheson Industries, Inc. Multiple spray nozzles
US4663433A (en) * 1985-12-23 1987-05-05 General Electric Company Separation of cyclic oligomeric carbonate from high molecular weight polycarbonate
JPS62289257A (ja) * 1986-06-09 1987-12-16 Ikeuchi:Kk 超微霧噴射ノズル
US4915302A (en) * 1988-03-30 1990-04-10 Kraus Robert A Device for making artificial snow
US5004351A (en) * 1988-04-18 1991-04-02 Minnesota Mining & Manufacturing Company Reaction injection molding machine
US4952224A (en) * 1989-04-17 1990-08-28 Canadian Oxygen Limited Method and apparatus for cryogenic crystallization of fats
US5011293A (en) * 1989-10-12 1991-04-30 The United States Of America As Represented By The Secretary Of The Army Emulsifier mixing cell
US5074671A (en) * 1990-11-13 1991-12-24 Dew Engineering And Development Limited Mixing apparatus

Also Published As

Publication number Publication date
JP3282731B2 (ja) 2002-05-20
JPH04231960A (ja) 1992-08-20
EP0461930B1 (en) 1995-09-13
DE69112917D1 (de) 1995-10-19
DE69112917T2 (de) 1996-05-15
US5314506A (en) 1994-05-24
IE912044A1 (en) 1991-12-18
CA2044706A1 (en) 1991-12-16
EP0461930A1 (en) 1991-12-18
CA2044706C (en) 2003-02-25
IE67187B1 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
ES2078447T3 (es) Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
IT1076217B (it) Procedimento per la limitazione della crescita in grandezza di piante e contenitore per la realizzazione del procedimento
AT304470B (de) Verfahren zur Herstellung von neuen substituierten 1-Amino-2-hydroxy-3-[2'cyclopentylphenoxy]-propanen, deren optisch aktiven Isomeren und Salzen
AT276640B (de) Verfahren zur Herstellung von neuen N<6>-Aralkyl-adenosin-derivaten
IT1224594B (it) Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene
IT1039021B (it) Derivati del 2 fenil indolo e procedimento per la loro preparazione
IT961170B (it) Derivati 2 imidazolidinonici proce dimento per la loro preparazione e loro impiego come erbicidi
IT1003536B (it) Derivati acilidrazonici procedi mento per la loro preparazione e loro impiego per stabilizzare materiali organici
IT1115221B (it) Acidi 2-sostituiti-4-aril-5-tiazolcarbossilici e loro derivati quali agenti di salvaguardia in colture di riso
MX161742A (es) Mejoras en aparato para probar el funcionamiento del higado
IT8148859A0 (it) Derivati del 3-amminopropossibenze ne loro preparazione e loro impiegocome medicamenti
IT987882B (it) Coloranti azalattonici idroinsolu bili e procedimento per la loro preparazione
IT1046929B (it) Derivati del pregnano e procedimento per la loro preparazione
GB574201A (en) Improvements in or relating to coverlet holders for sick-beds
IT1031004B (it) Derivati sustititti con sostituenti basic delli 2 3 benzo triazin 4 3h one e procedimento per la loro preparazione
AT299187B (de) Verfahren zur Herstellung von neuen Imidazo[2, 1-a]-isoindolderivaten und ihren Salzen
IT979871B (it) Composti di tipo cumarinico procedimento per prepararli e loro impiego per la tintura di composti organici
USD207967S (en) Flood light for photographers or the like
IT1069661B (it) Composizione antisolare contenent derivati del 2 fenil indolo
IT8024862A0 (it) L'applicazione in terapeutica come agenti analgesici dei derivati del 4,5,6,7-tetraidroisossazolo (5,4-c)piridin-3-ol
USD214632S (en) Work desk for a beautician
USD215873S (en) High intensity lamp
BE751862A (fr) Procede d'activation des proprietes emissives des monocristaux utilisescomme source de lumiere coherente
JPS53681A (en) Lighting fixture
USD232656S (en)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 461930

Country of ref document: ES